Analytical Data
-
基因名
SF3B14
- Application
-
别名
SF3B6;SAP14;SF3B14;SF3B14A;Splicing factor 3B subunit 6
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y3B4
-
表达区间
1-125aa
-
氨基酸序列
MGSSHHHHHH SSGLVPRGSH MAMQAAKRAN IRLPPEVNRI LYIRNLPYKI TAEEMYDIFG KYGPIRQIRV GNTPETRGTA YVVYEDIFDA KNACDHLSGF NVCNRYLVVL YYNANRAFQK MDTKKKEEQL KLLKEKYGIN TDPPK
-
分子量
17 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SF3B14 is a vital component of the spliceosome, a complex responsible for pre-mRNA splicing, which is a crucial process in gene expression regulation. Aberrations in splicing mechanisms are linked to various diseases, including cancer, neurodegenerative disorders, and genetic diseases, highlighting the importance of understanding the functional roles of spliceosomal components. Research on SF3B14 specifically focuses on its role in splice site recognition and the modulation of splicing efficiency, as well as its interactions with other splicing factors. Recent studies have indicated that SF3B14 may have implications in alternative splicing regulation, influencing the diversity of the transcriptome and, subsequently, protein diversity. Moreover, as SF3B14 is part of the larger SF3B complex, understanding its structure and function could pave the way for the development of targeted therapies that address splicing-related pathologies. By characterizing the SF3B14 recombinant protein, researchers aim to elucidate its molecular mechanisms and potential as a therapeutic target, fostering advancements in the treatment of splicing-related diseases.
